At the end of the 52-week study period, approximately how many patients achieved American College of Rheumatology (ACR) criteria for 20% improvement in their signs and symptoms of psoriatic arthritis after receiving the 100-mg Q12W dosing of tildrakizumab, the FDA-approved administration schedule for psoriasis?
A survey of patients with psoriatic disease found many respondents reported that their current disease, clinically considered to have limited skin involvement, was moderate to severe in severity. The results of the survey were published as a poster presented at Maui Derm Connect.
According to a survey of derms by Strober et al, the clinical manifestations of skin symptoms are the driving factor in the selection of treatment options for GPP. The results and analysis of the survey were presented at Maui Derm Connect 2021.
According to a poster abstract by Wu et al presented at Maui Derm Connect 2021, dose escalation was significantly lower with one IL-23 inhibitor vs all other available biologics for the treatment of moderate to severe plaque psoriasis.
In their poster presented at Maui Derm Connect, Fernandez et al found patients with metabolic syndrome who received tildrakizumab 100 mg were more likely to develop the treatment-emergent adverse events over a 5-year period.